Funding
ML-21683
Open Access funding enabled and organized by Projekt DEAL. The HD18 trial was funded by the Deutsche Krebshilfe (107957 and 110617) and the Swiss State Secretariat for Education, Research and Innovation (SERI) and supported by Roche Pharma AG (ML-21683)